About Contact Us Careers

CAR T-Cell Therapy Market - Top Companies and Manufacturers

Request Free Sample Copy

Report ID: 2441
Published Date: Dec 23, 2024
Report Format: PDF, PPT

Buy Now

Companies Dominating the CAR T-Cell Therapy Landscape

Novartis International AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Gilead Sciences, Inc.
Pfizer Inc.
Johnson & Johnson
Amgen Inc.
Bellicum Pharmaceuticals, Inc.
Immune Therapeutics
Sorrento Therapeutics
Celgene Corporation
Bluebird Bio

Browse Key Market Insights with Data Illustration:

CAR T-Cell Therapy Market Size & Share, Growth Forecasts 2037

In the News

Author Credits: Radhika Pawar

Report ID: 2441
Published Date: Dec 23, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of CAR T-cell therapy is estimated at USD 7.28 billion.

CAR T-Cell Therapy Market size was valued at USD 5.9 billion in 2024 and is likely to cross USD 140.25 billion by 2037, registering more than 27.6% CAGR during the forecast period i.e., between 2025-2037.

North America industry is predicted to account for largest revenue share by 2037, attributed to growing research and developments taking place in the field of CAR T cell therapy and cancer treatments in the region along with increasing number of treatments receiving approval by the U.S. Food and Drug Administration (FDA).

The major players in the market are Novartis International AG, Gilead Sciences, Inc., Pfizer Inc., Johnson & Johnson, Amgen Inc., Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Sorrento Therapeutics, Celgene Corporation and Bluebird Bio.

Inquiry Before Buying Request Free Sample